Targeting of identified HDAC, ATM, and p38 pathways shows radiosensitizing potential in cancer cells, and the clinically approved HDAC inhibitor vorinostat (SAHA) significantly improves the efficacy of TAT in vivo. This evidence concerns the gene MAPK14 and cancer.